These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 21291831

  • 1. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
    Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM.
    J Clin Lipidol; 2009 Oct; 3(5):332-40. PubMed ID: 21291831
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [Abstract] [Full Text] [Related]

  • 3. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

  • 4. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 Aug 15; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 5. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH.
    Lipids Health Dis; 2015 Sep 02; 14():98. PubMed ID: 26328624
    [Abstract] [Full Text] [Related]

  • 6. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
    Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM, COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.
    Am J Cardiol; 2010 May 15; 105(10):1409-12. PubMed ID: 20451686
    [Abstract] [Full Text] [Related]

  • 7. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia.
    Maki KC, Lubin BC, Reeves MS, Dicklin MR, Harris WS.
    J Clin Lipidol; 2009 Feb 15; 3(1):33-8. PubMed ID: 21291786
    [Abstract] [Full Text] [Related]

  • 8. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
    Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E.
    Curr Med Res Opin; 2010 Apr 15; 26(4):907-15. PubMed ID: 20156032
    [Abstract] [Full Text] [Related]

  • 9. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH.
    J Clin Lipidol; 2014 Apr 15; 8(1):94-106. PubMed ID: 24528690
    [Abstract] [Full Text] [Related]

  • 10. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.
    J Clin Lipidol; 2012 Apr 15; 6(6):565-72. PubMed ID: 23312052
    [Abstract] [Full Text] [Related]

  • 11. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia.
    Maki KC, Lawless AL, Kelley KM, Dicklin MR, Kaden VN, Schild AL, Rains TM, Marshall JW.
    J Cardiovasc Pharmacol; 2011 Apr 15; 57(4):489-94. PubMed ID: 21297494
    [Abstract] [Full Text] [Related]

  • 12. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
    Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA.
    J Cardiovasc Pharmacol; 2009 Sep 15; 54(3):196-203. PubMed ID: 19597368
    [Abstract] [Full Text] [Related]

  • 13. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
    Morton AM, Furtado JD, Lee J, Amerine W, Davidson MH, Sacks FM.
    J Clin Lipidol; 2016 Sep 15; 10(6):1442-1451.e4. PubMed ID: 27919362
    [Abstract] [Full Text] [Related]

  • 14. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov 15; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 15. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
    Bays HE, Maki KC, Doyle RT, Stein E.
    Postgrad Med; 2009 Sep 15; 121(5):145-50. PubMed ID: 19820283
    [Abstract] [Full Text] [Related]

  • 16. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH.
    Clin Ther; 2013 Sep 15; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [Abstract] [Full Text] [Related]

  • 17. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
    Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT, Soni PN, Juliano RA.
    J Clin Lipidol; 2015 Sep 15; 9(3):377-83. PubMed ID: 26073397
    [Abstract] [Full Text] [Related]

  • 18. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
    Savinova OV, Fillaus K, Harris WS, Shearer GC.
    Atherosclerosis; 2015 Jun 15; 240(2):520-5. PubMed ID: 25932792
    [Abstract] [Full Text] [Related]

  • 19. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects.
    Kearney T, de Gallegos CN, Proudler A, Parker K, Anayaoku V, Bannister P, Venkatesan S, Johnston DG.
    Metabolism; 2003 Jan 15; 52(1):50-9. PubMed ID: 12524662
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 15; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.